Geoffrey S Gottlieb, Ndeye Mery Dia Badiane, Stephen E Hawes, Louise Fortes, Macoumba Toure, Cheikh T Ndour, Alison K Starling, Fatou Traore, Fatima Sall, Kim G Wong, Stephen L Cherne, Donovan J Anderson, Stefanie A Dye, Robert A Smith, James I Mullins, Nancy B Kiviat, Papa Salif Sow
BACKGROUND: The efficacy of various antiretroviral (ARV) therapy regimens for human immunodeficiency virus type 2 (HIV-2) infection remains unclear. HIV-2 is intrinsically resistant to the nonnucleoside reverse-transcriptase inhibitors and to enfuvirtide and may also be less susceptible than HIV-1 to some protease inhibitors (PIs). However, the mutations in HIV-2 that confer ARV resistance are not well characterized. METHODS: Twenty-three patients were studied as part of an ongoing prospective longitudinal cohort study of ARV therapy for HIV-2 infection in Senegal...
February 15, 2009: Clinical Infectious Diseases